drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01156 | DB01246 | 593 | 820 | [
"DDInter252",
"DDInter45"
] | Bupropion | Alimemazine | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | A phenothiazine derivative that is used as an antipruritic. | Major | 2 | [
[
[
593,
25,
820
]
],
[
[
593,
24,
358
],
[
358,
24,
820
]
],
[
[
593,
64,
104
],
[
104,
40,
820
]
],
[
[
593,
64,
401
],
[
401,
24,... | [
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alimemazine"
]
],
[
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
],
[
"Orphenadr... | Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Bupropion may lead to a major life threatening interaction when taken with Methdilazine and Methdilazine (Co... |
DB00704 | DB12674 | 267 | 975 | [
"DDInter1263",
"DDInter1105"
] | Naltrexone | Lurbinectedin | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent fou... | Moderate | 1 | [
[
[
267,
24,
975
]
],
[
[
267,
24,
1613
],
[
1613,
24,
975
]
],
[
[
267,
24,
159
],
[
159,
63,
975
]
],
[
[
267,
63,
372
],
[
372,
2... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
... | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00604 | DB08864 | 1,425 | 786 | [
"DDInter385",
"DDInter1595"
] | Cisapride | Rilpivirine | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Major | 2 | [
[
[
1425,
25,
786
]
],
[
[
1425,
24,
655
],
[
655,
1,
786
]
],
[
[
1425,
6,
8374
],
[
8374,
45,
786
]
],
[
[
1425,
23,
112
],
[
112,
... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilpivirine"
]
],
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
],
[
"Etravirine"... | Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine (Compound) resembles Rilpivirine (Compound)
Cisapride (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rilpivirine (Compound)
Cisapride may cause a minor interaction that can limit clinical ef... |
DB00843 | DB11837 | 479 | 1,297 | [
"DDInter583",
"DDInter1351"
] | Donepezil | Osilodrostat | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
479,
24,
1297
]
],
[
[
479,
24,
112
],
[
112,
23,
1297
]
],
[
[
479,
24,
1320
],
[
1320,
63,
1297
]
],
[
[
479,
63,
353
],
[
353,
... | [
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[... | Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elag... |
DB00418 | DB12015 | 536 | 1,033 | [
"DDInter1650",
"DDInter53"
] | Secobarbital | Alpelisib | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
536,
24,
1033
]
],
[
[
536,
24,
1135
],
[
1135,
23,
1033
]
],
[
[
536,
24,
1344
],
[
1344,
24,
1033
]
],
[
[
536,
25,
126
],
[
126,
... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Alpelisib
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Cana... |
DB00414 | DB00951 | 590 | 1,072 | [
"DDInter16",
"DDInter986"
] | Acetohexamide | Isoniazid | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Moderate | 1 | [
[
[
590,
24,
1072
]
],
[
[
590,
24,
1486
],
[
1486,
62,
1072
]
],
[
[
590,
24,
870
],
[
870,
23,
1072
]
],
[
[
590,
63,
417
],
[
417,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Isoniazid
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Fl... |
DB08930 | DB08938 | 1,459 | 1,384 | [
"DDInter582",
"DDInter1112"
] | Dolutegravir | Magaldrate | Dolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity. Dolutegravir was developed by ViiV Healthcare and ... | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Major | 2 | [
[
[
1459,
25,
1384
]
],
[
[
1459,
62,
1220
],
[
1220,
23,
1384
]
],
[
[
1459,
25,
428
],
[
428,
63,
1384
]
],
[
[
1459,
62,
478
],
[
478,
... | [
[
[
"Dolutegravir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Magaldrate"
]
],
[
[
"Dolutegravir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
],
[
"Dexam... | Dolutegravir may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Dolutegravir may lead to a major life threatening interaction when taken with Ferrous fumarate and Ferrous f... |
DB00215 | DB00486 | 1,230 | 1,614 | [
"DDInter388",
"DDInter1253"
] | Citalopram | Nabilone | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Moderate | 1 | [
[
[
1230,
24,
1614
]
],
[
[
1230,
24,
530
],
[
530,
1,
1614
]
],
[
[
1230,
21,
28863
],
[
28863,
60,
1614
]
],
[
[
1230,
24,
999
],
[
999,... | [
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
... | Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol (Compound) resembles Nabilone (Compound)
Citalopram (Compound) causes Lightheadedness (Side Effect) and Lightheadedness (Side Effect) is caused by Nabilone (Compound)
Citalopram may cause a moderate inte... |
DB00704 | DB01406 | 267 | 984 | [
"DDInter1263",
"DDInter472"
] | Naltrexone | Danazol | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. | Moderate | 1 | [
[
[
267,
24,
984
]
],
[
[
267,
24,
1546
],
[
1546,
1,
984
]
],
[
[
267,
63,
1026
],
[
1026,
40,
984
]
],
[
[
267,
7,
3932
],
[
3932,
... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danazol"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyltestosterone"
],
... | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Methyltestosterone and Methyltestosterone (Compound) resembles Danazol (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone and Oxandrolone (Compound) resembles Danazol... |
DB09100 | DB13142 | 320 | 841 | [
"DDInter1799",
"DDInter274"
] | Thyroid, porcine | Calcium glubionate anhydrous | Thyroid extract is dried and powdered thyroid glands from pigs containing tiiodothyronine (T3) and thyroxine (T4) used to supplement low or absent thyroid activity.[A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891 but its use dates back as far as the 6th century. Thyro... | Calcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets. | Moderate | 1 | [
[
[
320,
24,
841
]
],
[
[
320,
63,
1231
],
[
1231,
24,
841
]
],
[
[
320,
63,
1283
],
[
1283,
24,
255
],
[
255,
24,
841
]
],
[
[
320,
... | [
[
[
"Thyroid, porcine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Thyroid, porcine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Thyroid, porcine may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer and Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Thyroid, porcine may cause a moderate interaction that could exacerbate diseases when take... |
DB00912 | DB01039 | 473 | 535 | [
"DDInter1581",
"DDInter718"
] | Repaglinide | Fenofibrate | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil]. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993. | Moderate | 1 | [
[
[
473,
24,
535
]
],
[
[
473,
63,
831
],
[
831,
1,
535
]
],
[
[
473,
6,
3486
],
[
3486,
45,
535
]
],
[
[
473,
21,
28851
],
[
28851,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenofibrate"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
],
... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin (Compound) resembles Fenofibrate (Compound)
Repaglinide (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Fenofibrate (Compound)
Repaglinide (Compound) causes Hepatic enzyme increased (Si... |
DB06691 | DB09272 | 849 | 412 | [
"DDInter1155",
"DDInter632"
] | Mepyramine | Eluxadoline | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
849,
24,
412
]
],
[
[
849,
63,
1594
],
[
1594,
24,
412
]
],
[
[
849,
74,
100
],
[
100,
24,
412
]
],
[
[
849,
24,
1536
],
[
1536,
... | [
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Mepyramine (Compound) resembles Brompheniramine (Compound) and Mepyramine may cause a moderate interaction that... |
DB01244 | DB09049 | 762 | 1,135 | [
"DDInter192",
"DDInter1261"
] | Bepridil | Naloxegol | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Minor | 0 | [
[
[
762,
23,
1135
]
],
[
[
762,
25,
971
],
[
971,
62,
1135
]
],
[
[
762,
64,
1424
],
[
1424,
23,
1135
]
],
[
[
762,
25,
1069
],
[
1069,
... | [
[
[
"Bepridil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
]
],
[
[
"Bepridil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
... | Bepridil may lead to a major life threatening interaction when taken with Gilteritinib and Gilteritinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Bepridil may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a minor interaction that... |
DB00294 | DB06335 | 1,336 | 761 | [
"DDInter701",
"DDInter1646"
] | Etonogestrel | Saxagliptin | Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001. | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
1336,
24,
761
]
],
[
[
1336,
6,
8374
],
[
8374,
45,
761
]
],
[
[
1336,
21,
28966
],
[
28966,
60,
761
]
],
[
[
1336,
24,
1296
],
[
1296... | [
[
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Etonogestrel",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Etonogestrel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Saxagliptin (Compound)
Etonogestrel (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Saxagliptin (Compound)
Etonogestrel may cause a moderate interaction that could... |
DB00872 | DB09073 | 1,080 | 951 | [
"DDInter438",
"DDInter1379"
] | Conivaptan | Palbociclib | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Major | 2 | [
[
[
1080,
25,
951
]
],
[
[
1080,
25,
1476
],
[
1476,
63,
951
]
],
[
[
1080,
24,
710
],
[
710,
63,
951
]
],
[
[
1080,
64,
467
],
[
467,
... | [
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
]
],
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} ... | Conivaptan may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib and Binimetinib may cau... |
DB00196 | DB00213 | 600 | 837 | [
"DDInter743",
"DDInter1388"
] | Fluconazole | Pantoprazole | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | Moderate | 1 | [
[
[
600,
24,
837
]
],
[
[
600,
24,
1215
],
[
1215,
40,
837
]
],
[
[
600,
6,
6017
],
[
6017,
45,
837
]
],
[
[
600,
21,
29455
],
[
29455,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pantoprazole"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
],
... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole (Compound) resembles Pantoprazole (Compound)
Fluconazole (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Pantoprazole (Compound)
Fluconazole (Compound) causes Agranulocytosis (Side Effe... |
DB00289 | DB12141 | 847 | 971 | [
"DDInter132",
"DDInter817"
] | Atomoxetine | Gilteritinib | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
847,
24,
971
]
],
[
[
847,
23,
112
],
[
112,
23,
971
]
],
[
[
847,
24,
485
],
[
485,
24,
971
]
],
[
[
847,
24,
823
],
[
823,
63,... | [
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Atomoxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Atomoxetine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and... |
DB00584 | DB06715 | 610 | 239 | [
"DDInter638",
"DDInter1500"
] | Enalapril | Potassium Iodide | Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypert... | Saturated solution of Potassium Iodide (SSKI) is used pharmaceutically for emergency use in patients experiencing acute symptoms of severe hyperthyroidism (also known as thyroid storm or thyrotoxic crisis). SSKI can also be used for radioiodine-contamination emergencies or in preparation of thyrotoxic patients for thyr... | Major | 2 | [
[
[
610,
25,
239
]
],
[
[
610,
21,
29196
],
[
29196,
60,
239
]
],
[
[
610,
24,
1274
],
[
1274,
24,
239
]
],
[
[
610,
1,
954
],
[
954,
... | [
[
[
"Enalapril",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium Iodide"
]
],
[
[
"Enalapril",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Effect) is caused by... | Enalapril (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Potassium Iodide (Compound)
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when take... |
DB01169 | DB09080 | 57 | 144 | [
"DDInter120",
"DDInter1331"
] | Arsenic trioxide | Olodaterol | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
57,
24,
144
]
],
[
[
57,
62,
1247
],
[
1247,
23,
144
]
],
[
[
57,
64,
956
],
[
956,
24,
144
]
],
[
[
57,
25,
371
],
[
371,
24,
... | [
[
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Arsenic trioxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"... | Arsenic trioxide may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Olodaterol
Arsenic trioxide may lead to a major life threatening interaction when taken with Norfloxacin and ... |
DB01285 | DB09268 | 708 | 1,662 | [
"DDInter445",
"DDInter1464"
] | Corticotropin | Picosulfuric acid | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
708,
24,
1662
]
],
[
[
708,
63,
997
],
[
997,
24,
1662
]
],
[
[
708,
24,
877
],
[
877,
63,
1662
]
],
[
[
708,
24,
1372
],
[
1372,
... | [
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"... | Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide and Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Ma... |
DB01041 | DB09078 | 770 | 1,228 | [
"DDInter1789",
"DDInter1036"
] | Thalidomide | Lenvatinib | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
770,
24,
1228
]
],
[
[
770,
63,
112
],
[
112,
23,
1228
]
],
[
[
770,
63,
1100
],
[
1100,
24,
1228
]
],
[
[
770,
24,
938
],
[
938,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and... |
DB00446 | DB06077 | 597 | 879 | [
"DDInter351",
"DDInter1102"
] | Chloramphenicol | Lumateperone | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Moderate | 1 | [
[
[
597,
24,
879
]
],
[
[
597,
24,
214
],
[
214,
63,
879
]
],
[
[
597,
24,
392
],
[
392,
24,
879
]
],
[
[
597,
63,
245
],
[
245,
24,... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Lapat... |
DB00222 | DB09038 | 245 | 1,450 | [
"DDInter825",
"DDInter636"
] | Glimepiride | Empagliflozin | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
245,
24,
1450
]
],
[
[
245,
23,
1103
],
[
1103,
23,
1450
]
],
[
[
245,
24,
461
],
[
461,
24,
1450
]
],
[
[
245,
63,
1028
],
[
1028,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Glimepiride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[... | Glimepiride may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Empagliflozin
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol ... |
DB00530 | DB01319 | 1,195 | 34 | [
"DDInter667",
"DDInter777"
] | Erlotinib | Fosamprenavir | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Moderate | 1 | [
[
[
1195,
24,
34
]
],
[
[
1195,
24,
1091
],
[
1091,
40,
34
]
],
[
[
1195,
6,
8374
],
[
8374,
45,
34
]
],
[
[
1195,
21,
29062
],
[
29062,
... | [
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
],
[
... | Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir (Compound) resembles Fosamprenavir (Compound)
Erlotinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fosamprenavir (Compound)
Erlotinib (Compound) causes Neutropenia (Side Effect) and Neut... |
DB09098 | DB09118 | 98 | 1,580 | [
"DDInter1700",
"DDInter1711"
] | Somatrem | Stiripentol | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate. Such discussion revolves around whether patients' natural dispo... | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Moderate | 1 | [
[
[
98,
24,
1580
]
],
[
[
98,
24,
466
],
[
466,
62,
1580
]
],
[
[
98,
63,
1409
],
[
1409,
24,
1580
]
],
[
[
98,
24,
283
],
[
283,
63... | [
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
... | Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Stiripentol
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban ... |
DB00637 | DB06663 | 1,557 | 1,154 | [
"DDInter128",
"DDInter1398"
] | Astemizole | Pasireotide | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
1557,
25,
1154
]
],
[
[
1557,
23,
112
],
[
112,
23,
1154
]
],
[
[
1557,
25,
1662
],
[
1662,
63,
1154
]
],
[
[
1557,
24,
1017
],
[
1017... | [
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Astemizole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Astemizole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pasireotide
Astemizole may lead to a major life threatening interaction when taken with Picosulfuric acid and Picosulfuri... |
DB00014 | DB01261 | 521 | 170 | [
"DDInter839",
"DDInter1679"
] | Goserelin | Sitagliptin | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Moderate | 1 | [
[
[
521,
24,
170
]
],
[
[
521,
21,
28850
],
[
28850,
60,
170
]
],
[
[
521,
24,
52
],
[
52,
62,
170
]
],
[
[
521,
24,
623
],
[
623,
2... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Goserelin",
"{u} (Compound) causes {v} (Side Effect)",
"Back pain"
],
[
"Back pain",
"{u} (Side Effect) is cause... | Goserelin (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Sitagliptin (Compound)
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a minor interaction that can limit clinical effects when taken with Sitaglip... |
DB01136 | DB09564 | 772 | 1,296 | [
"DDInter305",
"DDInter930"
] | Carvedilol | Insulin degludec | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
772,
24,
1296
]
],
[
[
772,
63,
1411
],
[
1411,
24,
1296
]
],
[
[
772,
25,
659
],
[
659,
24,
1296
]
],
[
[
772,
24,
1151
],
[
1151,
... | [
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
... | Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Carvedilol may lead to a major life threatening interaction when taken with Vilanterol and Vilanterol ma... |
DB06168 | DB09312 | 1,531 | 967 | [
"DDInter281",
"DDInter103"
] | Canakinumab | Antilymphocyte immunoglobulin (horse) | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The... | Moderate | 1 | [
[
[
1531,
63,
967
]
],
[
[
1531,
23,
1193
],
[
1193,
62,
967
]
],
[
[
1531,
62,
1461
],
[
1461,
62,
967
]
],
[
[
1531,
63,
1683
],
[
1683,... | [
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Antilymphocyte immunoglobulin (horse)"
]
],
[
[
"Canakinumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"... | Canakinumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Antilymphocyte immunoglobulin (horse)
Canakinumab may cause a minor interaction that can limit clinical effects when t... |
DB00328 | DB11703 | 831 | 405 | [
"DDInter921",
"DDInter9"
] | Indomethacin | Acalabrutinib | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlor... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
831,
25,
405
]
],
[
[
831,
23,
1384
],
[
1384,
24,
405
]
],
[
[
831,
24,
1619
],
[
1619,
63,
405
]
],
[
[
831,
24,
121
],
[
121,
... | [
[
[
"Indomethacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Indomethacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
],
[
"Magal... | Indomethacin may cause a minor interaction that can limit clinical effects when taken with Magaldrate and Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Ru... |
DB00075 | DB01362 | 541 | 497 | [
"DDInter1250",
"DDInter960"
] | Muromonab | Iohexol | Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. Muromonab is 93% monomeric immune globulin G type... | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
541,
25,
497
]
],
[
[
541,
24,
1267
],
[
1267,
64,
497
]
],
[
[
541,
25,
534
],
[
534,
25,
497
]
],
[
[
541,
24,
1503
],
[
1503,
... | [
[
[
"Muromonab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Muromonab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifampridine"
],
[
"Amifampridin... | Muromonab may cause a moderate interaction that could exacerbate diseases when taken with Amifampridine and Amifampridine may lead to a major life threatening interaction when taken with Iohexol
Muromonab may lead to a major life threatening interaction when taken with Tramadol and Tramadol may lead to a major life thr... |
DB00013 | DB00758 | 1,255 | 1,347 | [
"DDInter1905",
"DDInter413"
] | Urokinase | Clopidogrel | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Moderate | 1 | [
[
[
1255,
24,
1347
]
],
[
[
1255,
24,
1018
],
[
1018,
25,
1347
]
],
[
[
1255,
23,
539
],
[
539,
62,
1347
]
],
[
[
1255,
24,
958
],
[
958,
... | [
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
]
],
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
... | Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Clopidogrel
Urokinase may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a min... |
DB01087 | DB04868 | 1,520 | 478 | [
"DDInter1520",
"DDInter1293"
] | Primaquine | Nilotinib | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
1520,
25,
478
]
],
[
[
1520,
6,
8374
],
[
8374,
45,
478
]
],
[
[
1520,
18,
8800
],
[
8800,
57,
478
]
],
[
[
1520,
21,
28900
],
[
28900... | [
[
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Primaquine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Nilotini... | Primaquine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nilotinib (Compound)
Primaquine (Compound) downregulates RBM34 (Gene) and RBM34 (Gene) is downregulated by Nilotinib (Compound)
Primaquine (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Nilotinib (Compo... |
DB00295 | DB00341 | 475 | 1,242 | [
"DDInter1244",
"DDInter343"
] | Morphine | Cetirizine | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms , . One of the most common uses for this drug is for a condition called _alle... | Moderate | 1 | [
[
[
475,
24,
1242
]
],
[
[
475,
24,
537
],
[
537,
63,
1242
]
],
[
[
475,
25,
1630
],
[
1630,
63,
1242
]
],
[
[
475,
21,
28841
],
[
28841,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Morphine may lead to a major life threatening interaction when taken with Perphenazine and Perphenazine may cause a ... |
DB00197 | DB12010 | 1,324 | 214 | [
"DDInter1881",
"DDInter785"
] | Troglitazone | Fostamatinib | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
1324,
24,
214
]
],
[
[
1324,
24,
976
],
[
976,
24,
214
]
],
[
[
1324,
24,
861
],
[
861,
63,
214
]
],
[
[
1324,
25,
879
],
[
879,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib an... |
DB00373 | DB00443 | 461 | 251 | [
"DDInter1809",
"DDInter195"
] | Timolol | Betamethasone | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective ag... | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Moderate | 1 | [
[
[
461,
24,
251
]
],
[
[
461,
24,
617
],
[
617,
40,
251
]
],
[
[
461,
24,
870
],
[
870,
1,
251
]
],
[
[
461,
6,
4973
],
[
4973,
45,... | [
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
]
],
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
... | Timolol may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide (Compound) resembles Betamethasone (Compound)
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Betamethasone (... |
DB00056 | DB11003 | 816 | 748 | [
"DDInter814",
"DDInter100"
] | Gemtuzumab ozogamicin | Anthrax vaccine | Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheami... | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
816,
24,
748
]
],
[
[
816,
24,
322
],
[
322,
24,
748
]
],
[
[
816,
25,
676
],
[
676,
63,
748
]
],
[
[
816,
64,
1057
],
[
1057,
2... | [
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"... | Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Gemtuzumab ozogamicin may lead to a major life threatening interaction when taken with Upadaciti... |
DB00619 | DB04861 | 1,419 | 1,592 | [
"DDInter909",
"DDInter1271"
] | Imatinib | Nebivolol | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Moderate | 1 | [
[
[
1419,
24,
1592
]
],
[
[
1419,
6,
12523
],
[
12523,
45,
1592
]
],
[
[
1419,
21,
28762
],
[
28762,
60,
1592
]
],
[
[
1419,
24,
578
],
[
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
]
],
[
[
"Imatinib",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
... | Imatinib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Nebivolol (Compound)
Imatinib (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nebivolol (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may... |
DB06700 | DB06810 | 643 | 397 | [
"DDInter511",
"DDInter1484"
] | Desvenlafaxine | Plicamycin | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of ad... | Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000. | Moderate | 1 | [
[
[
643,
24,
397
]
],
[
[
643,
63,
885
],
[
885,
24,
397
]
],
[
[
643,
40,
1100
],
[
1100,
24,
397
]
],
[
[
643,
24,
578
],
[
578,
6... | [
[
[
"Desvenlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plicamycin"
]
],
[
[
"Desvenlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]... | Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Plicamycin
Desvenlafaxine (Compound) resembles Venlafaxine (Compound) and Venlafaxine may cause a moderate interact... |
DB00533 | DB09030 | 1,416 | 840 | [
"DDInter1613",
"DDInter1945"
] | Rofecoxib | Vorapaxar | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene m... | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Moderate | 1 | [
[
[
1416,
24,
840
]
],
[
[
1416,
24,
885
],
[
885,
24,
840
]
],
[
[
1416,
63,
1061
],
[
1061,
24,
840
]
],
[
[
1416,
63,
702
],
[
702,
... | [
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorapaxar"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
... | Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Tre... |
DB00445 | DB14509 | 322 | 1,399 | [
"DDInter655",
"DDInter1081"
] | Epirubicin | Lithium carbonate | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
322,
24,
1399
]
],
[
[
322,
24,
589
],
[
589,
23,
1399
]
],
[
[
322,
24,
1374
],
[
1374,
24,
1399
]
],
[
[
322,
63,
1010
],
[
1010,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
],
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Ab... |
DB00358 | DB06176 | 1,010 | 1,342 | [
"DDInter1140",
"DDInter1616"
] | Mefloquine | Romidepsin | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
1010,
24,
1342
]
],
[
[
1010,
23,
1247
],
[
1247,
23,
1342
]
],
[
[
1010,
24,
336
],
[
336,
24,
1342
]
],
[
[
1010,
24,
1616
],
[
1616... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Mefloquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Mefloquine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine an... |
DB08895 | DB11730 | 976 | 351 | [
"DDInter1825",
"DDInter1588"
] | Tofacitinib | Ribociclib | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
976,
25,
351
]
],
[
[
976,
24,
283
],
[
283,
62,
351
]
],
[
[
976,
63,
479
],
[
479,
23,
351
]
],
[
[
976,
64,
310
],
[
310,
24,... | [
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratin... | Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepez... |
DB00398 | DB04946 | 79 | 924 | [
"DDInter1702",
"DDInter907"
] | Sorafenib | Iloperidone | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Major | 2 | [
[
[
79,
25,
924
]
],
[
[
79,
24,
1664
],
[
1664,
1,
924
]
],
[
[
79,
25,
1425
],
[
1425,
25,
924
]
],
[
[
79,
24,
519
],
[
519,
40,
... | [
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
"Risperidon... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Sorafenib may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken... |
DB00570 | DB09074 | 147 | 1,362 | [
"DDInter1936",
"DDInter1327"
] | Vinblastine | Olaparib | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
147,
24,
1362
]
],
[
[
147,
24,
725
],
[
725,
63,
1362
]
],
[
[
147,
23,
896
],
[
896,
24,
1362
]
],
[
[
147,
24,
1683
],
[
1683,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Satralizumab"
],
[
... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab and Satralizumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Etoposide and Etopo... |
DB01357 | DB11767 | 890 | 1,583 | [
"DDInter1160",
"DDInter1643"
] | Mestranol | Sarilumab | The 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives. | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approve... | Moderate | 1 | [
[
[
890,
24,
1583
]
],
[
[
890,
1,
1336
],
[
1336,
24,
1583
]
],
[
[
890,
63,
58
],
[
58,
24,
1583
]
],
[
[
890,
24,
1683
],
[
1683,
... | [
[
[
"Mestranol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Mestranol",
"{u} (Compound) resembles {v} (Compound)",
"Etonogestrel"
],
[
"Etonogestrel",
"{u} may cause a modera... | Mestranol (Compound) resembles Etonogestrel (Compound) and Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Mestranol may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could ... |
DB04575 | DB14723 | 35 | 159 | [
"DDInter1555",
"DDInter1026"
] | Quinestrol | Larotrectinib | The 3-cyclopentyl ether of ethinyl estradiol. | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
35,
24,
159
]
],
[
[
35,
40,
1197
],
[
1197,
24,
159
]
],
[
[
35,
63,
1486
],
[
1486,
24,
159
]
],
[
[
35,
24,
1320
],
[
1320,
2... | [
[
[
"Quinestrol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Quinestrol",
"{u} (Compound) resembles {v} (Compound)",
"Norethisterone"
],
[
"Norethisterone",
"{u} may caus... | Quinestrol (Compound) resembles Norethisterone (Compound) and Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Quinestrol may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a mode... |
DB00397 | DB01240 | 1,466 | 885 | [
"DDInter1458",
"DDInter657"
] | Phenylpropanolamine | Epoprostenol | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
1466,
24,
885
]
],
[
[
1466,
63,
1061
],
[
1061,
1,
885
]
],
[
[
1466,
21,
28921
],
[
28921,
60,
885
]
],
[
[
1466,
63,
1252
],
[
1252... | [
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trepros... | Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Phenylpropanolamine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Epoprostenol (Compound)
Phenylpropanolamin... |
DB00668 | DB04946 | 874 | 924 | [
"DDInter652",
"DDInter907"
] | Epinephrine | Iloperidone | Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been avail... | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Moderate | 1 | [
[
[
874,
24,
924
]
],
[
[
874,
24,
1664
],
[
1664,
1,
924
]
],
[
[
874,
24,
519
],
[
519,
40,
924
]
],
[
[
874,
6,
5214
],
[
5214,
4... | [
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
... | Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone (Compound) resembles Iloperidone (... |
DB00491 | DB02546 | 127 | 137 | [
"DDInter1217",
"DDInter1947"
] | Miglitol | Vorinostat | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new clas... | Moderate | 1 | [
[
[
127,
24,
137
]
],
[
[
127,
21,
29519
],
[
29519,
60,
137
]
],
[
[
127,
63,
1685
],
[
1685,
24,
137
]
],
[
[
127,
24,
959
],
[
959,
... | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorinostat"
]
],
[
[
"Miglitol",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal symptom NOS"
],
[
"Gastrointestinal symptom NOS"... | Miglitol (Compound) causes Gastrointestinal symptom NOS (Side Effect) and Gastrointestinal symptom NOS (Side Effect) is caused by Vorinostat (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exa... |
DB00046 | DB00734 | 1,179 | 1,664 | [
"DDInter940",
"DDInter1605"
] | Insulin lispro | Risperidone | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Moderate | 1 | [
[
[
1179,
24,
1664
]
],
[
[
1179,
24,
924
],
[
924,
40,
1664
]
],
[
[
1179,
24,
1616
],
[
1616,
63,
1664
]
],
[
[
1179,
24,
999
],
[
999,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
]... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Iloperidone and Iloperidone (Compound) resembles Risperidone (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may cause a moderate interaction t... |
DB01232 | DB06663 | 1,327 | 1,154 | [
"DDInter1640",
"DDInter1398"
] | Saquinavir | Pasireotide | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
1327,
25,
1154
]
],
[
[
1327,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
1327,
62,
112
],
[
112,
23,
1154
]
],
[
[
1327,
24,
466
],
[
466... | [
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Saquinavir",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused b... | Saquinavir (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Saquinavir may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken... |
DB00712 | DB14730 | 1,274 | 1,412 | [
"DDInter763",
"DDInter264"
] | Flurbiprofen | Calaspargase pegol | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
1274,
24,
1412
]
],
[
[
1274,
25,
792
],
[
792,
24,
1412
]
],
[
[
1274,
24,
1347
],
[
1347,
24,
1412
]
],
[
[
1274,
64,
553
],
[
553,
... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Flurbiprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
],
[
... | Flurbiprofen may lead to a major life threatening interaction when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopid... |
DB05773 | DB14761 | 1,047 | 242 | [
"DDInter1848",
"DDInter1578"
] | Trastuzumab emtansine | Remdesivir | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends o... | Moderate | 1 | [
[
[
1047,
24,
242
]
],
[
[
1047,
63,
467
],
[
467,
24,
242
]
],
[
[
1047,
64,
1377
],
[
1377,
24,
242
]
],
[
[
1047,
24,
384
],
[
384,
... | [
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simva... | Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Trastuzumab emtansine may lead to a major life threatening interaction when taken with Leflunomide ... |
DB00382 | DB00835 | 62 | 100 | [
"DDInter1734",
"DDInter245"
] | Tacrine | Brompheniramine | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
62,
24,
100
]
],
[
[
62,
24,
128
],
[
128,
24,
100
]
],
[
[
62,
63,
1594
],
[
1594,
24,
100
]
],
[
[
62,
24,
1264
],
[
1264,
63,... | [
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
... | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Doxyla... |
DB00601 | DB01176 | 453 | 537 | [
"DDInter1073",
"DDInter453"
] | Linezolid | Cyclizine | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Moderate | 1 | [
[
[
453,
24,
537
]
],
[
[
453,
24,
104
],
[
104,
1,
537
]
],
[
[
453,
64,
1048
],
[
1048,
1,
537
]
],
[
[
453,
63,
13
],
[
13,
24,
... | [
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
... | Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Cyclizine (Compound)
Linezolid may lead to a major life threatening interaction when taken with Doxapram and Doxapram (Compound) resembles Cyclizine (Compound)
Linezolid may cause... |
DB01129 | DB11791 | 379 | 785 | [
"DDInter1559",
"DDInter287"
] | Rabeprazole | Capmatinib | Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion. | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Minor | 0 | [
[
[
379,
23,
785
]
],
[
[
379,
40,
837
],
[
837,
23,
785
]
],
[
[
379,
1,
1215
],
[
1215,
23,
785
]
],
[
[
379,
24,
98
],
[
98,
24,
... | [
[
[
"Rabeprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capmatinib"
]
],
[
[
"Rabeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} may cause a min... | Rabeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Capmatinib
Rabeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Capma... |
DB00373 | DB09080 | 461 | 144 | [
"DDInter1809",
"DDInter1331"
] | Timolol | Olodaterol | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective ag... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Major | 2 | [
[
[
461,
25,
144
]
],
[
[
461,
25,
1011
],
[
1011,
24,
144
]
],
[
[
461,
24,
1445
],
[
1445,
24,
144
]
],
[
[
461,
64,
1031
],
[
1031,
... | [
[
[
"Timolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olodaterol"
]
],
[
[
"Timolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may cau... | Timolol may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may ca... |
DB09122 | DB09472 | 1,613 | 1,383 | [
"DDInter1409",
"DDInter1693"
] | Peginterferon beta-1a | Sodium sulfate | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
1613,
24,
1383
]
],
[
[
1613,
63,
609
],
[
609,
24,
1383
]
],
[
[
1613,
24,
971
],
[
971,
63,
1383
]
],
[
[
1613,
64,
593
],
[
593,
... | [
[
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"C... | Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases whe... |
DB00444 | DB09098 | 63 | 98 | [
"DDInter1765",
"DDInter1700"
] | Teniposide | Somatrem | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
63,
24,
98
]
],
[
[
63,
63,
168
],
[
168,
23,
98
]
],
[
[
63,
24,
671
],
[
671,
24,
98
]
],
[
[
63,
24,
159
],
[
159,
63,
... | [
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somatrem
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastat... |
DB01148 | DB11130 | 1,128 | 407 | [
"DDInter738",
"DDInter1344"
] | Flavoxate | Opium | A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem] | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
1128,
24,
407
]
],
[
[
1128,
63,
662
],
[
662,
24,
407
]
],
[
[
1128,
24,
849
],
[
849,
24,
407
]
],
[
[
1128,
24,
1609
],
[
1609,
... | [
[
[
"Flavoxate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Flavoxate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
... | Flavoxate may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Flavoxate may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyram... |
DB00844 | DB01142 | 314 | 1,264 | [
"DDInter1257",
"DDInter593"
] | Nalbuphine | Doxepin | A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
314,
24,
1264
]
],
[
[
314,
24,
401
],
[
401,
24,
1264
]
],
[
[
314,
63,
832
],
[
832,
24,
1264
]
],
[
[
314,
24,
649
],
[
649,
... | [
[
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
... | Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and T... |
DB00586 | DB09030 | 1,512 | 840 | [
"DDInter537",
"DDInter1945"
] | Diclofenac | Vorapaxar | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Major | 2 | [
[
[
1512,
25,
840
]
],
[
[
1512,
23,
297
],
[
297,
62,
840
]
],
[
[
1512,
63,
1416
],
[
1416,
24,
840
]
],
[
[
1512,
24,
885
],
[
885,
... | [
[
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
]
],
[
[
"Diclofenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u}... | Diclofenac may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Vorapaxar
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Rofecoxib and Rofecoxib may cause a ... |
DB00193 | DB00405 | 534 | 128 | [
"DDInter1841",
"DDInter517"
] | Tramadol | Dexbrompheniramine | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Moderate | 1 | [
[
[
534,
24,
128
]
],
[
[
534,
24,
662
],
[
662,
63,
128
]
],
[
[
534,
24,
28
],
[
28,
1,
128
]
],
[
[
534,
18,
20113
],
[
20113,
57... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
... | Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl a... |
DB00443 | DB01067 | 251 | 959 | [
"DDInter195",
"DDInter826"
] | Betamethasone | Glipizide | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
251,
24,
959
]
],
[
[
251,
63,
245
],
[
245,
40,
959
]
],
[
[
251,
24,
1411
],
[
1411,
1,
959
]
],
[
[
251,
6,
8374
],
[
8374,
4... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Co... |
DB01069 | DB05812 | 401 | 1,374 | [
"DDInter1533",
"DDInter8"
] | Promethazine | Abiraterone | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
401,
24,
1374
]
],
[
[
401,
6,
12523
],
[
12523,
45,
1374
]
],
[
[
401,
21,
28809
],
[
28809,
60,
1374
]
],
[
[
401,
62,
112
],
[
112,... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Promethazine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compou... | Promethazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound)
Promethazine (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Abiraterone (Compound)
Promethazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole... |
DB00261 | DB01255 | 702 | 633 | [
"DDInter93",
"DDInter1078"
] | Anagrelide | Lisdexamfetamine | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved... | Major | 2 | [
[
[
702,
25,
633
]
],
[
[
702,
21,
28751
],
[
28751,
60,
633
]
],
[
[
702,
23,
112
],
[
112,
23,
633
]
],
[
[
702,
25,
1494
],
[
1494,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lisdexamfetamine"
]
],
[
[
"Anagrelide",
"{u} (Compound) causes {v} (Side Effect)",
"Convulsion"
],
[
"Convulsion",
"{u} (Side Effect) is caused by {... | Anagrelide (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Lisdexamfetamine (Compound)
Anagrelide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken wi... |
DB06710 | DB09054 | 1,546 | 384 | [
"DDInter1193",
"DDInter905"
] | Methyltestosterone | Idelalisib | A synthetic anabolic steroid used for treating men with testosterone deficiency or similar androgen replacement therapies. Also, has antineoplastic properties and so has been used secondarily in women with advanced breast cancer. Methyltestosterone is a schedule III drug in the US. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1546,
24,
384
]
],
[
[
1546,
63,
305
],
[
305,
24,
384
]
],
[
[
1546,
74,
891
],
[
891,
24,
384
]
],
[
[
1546,
1,
1687
],
[
1687,
... | [
[
[
"Methyltestosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Methyltestosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginas... | Methyltestosterone may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Methyltestosterone (Compound) resembles Prednisolone (Compound) an... |
DB01181 | DB10276 | 1,532 | 1,624 | [
"DDInter906",
"DDInter1623"
] | Ifosfamide | Rotavirus vaccine | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotar... | Major | 2 | [
[
[
1532,
25,
1624
]
],
[
[
1532,
63,
552
],
[
552,
25,
1624
]
],
[
[
1532,
64,
770
],
[
770,
25,
1624
]
],
[
[
1532,
25,
375
],
[
375,
... | [
[
[
"Ifosfamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
],
[
"Car... | Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may lead to a major life threatening interaction when taken with Rotavirus vaccine
Ifosfamide may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may lead to a ma... |
DB00361 | DB08870 | 134 | 850 | [
"DDInter1939",
"DDInter228"
] | Vinorelbine | Brentuximab vedotin | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
134,
24,
850
]
],
[
[
134,
24,
788
],
[
788,
24,
850
]
],
[
[
134,
24,
496
],
[
496,
63,
850
]
],
[
[
134,
25,
859
],
[
859,
24,... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Hepati... |
DB08865 | DB12240 | 1,593 | 110 | [
"DDInter448",
"DDInter1485"
] | Crizotinib | Polatuzumab vedotin | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable link... | Moderate | 1 | [
[
[
1593,
24,
110
]
],
[
[
1593,
25,
129
],
[
129,
23,
110
]
],
[
[
1593,
63,
467
],
[
467,
24,
110
]
],
[
[
1593,
64,
1213
],
[
1213,
... | [
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
... | Crizotinib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Polatuzumab vedotin
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastat... |
DB00877 | DB09043 | 629 | 135 | [
"DDInter1678",
"DDInter36"
] | Sirolimus | Albiglutide | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
629,
24,
135
]
],
[
[
629,
63,
1647
],
[
1647,
23,
135
]
],
[
[
629,
64,
362
],
[
362,
24,
135
]
],
[
[
629,
63,
870
],
[
870,
2... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[
... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Sirolimus may lead to a major life threatening interaction when taken with Phenytoin and Phenytoin may cause a moderat... |
DB00222 | DB00780 | 245 | 551 | [
"DDInter825",
"DDInter1440"
] | Glimepiride | Phenelzine | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name o... | Moderate | 1 | [
[
[
245,
24,
551
]
],
[
[
245,
24,
1161
],
[
1161,
40,
551
]
],
[
[
245,
63,
73
],
[
73,
25,
551
]
],
[
[
245,
21,
28722
],
[
28722,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selegiline"
],
[
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Selegiline and Selegiline (Compound) resembles Phenelzine (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may lead to a major life threatening in... |
DB00930 | DB02659 | 166 | 1,108 | [
"DDInter432",
"DDInter369"
] | Colesevelam | Cholic Acid | Colesevelam is a bile acid sequestrant. Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood. It works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in th... | A major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. [PubChem] Cholic acid, formulated as Cholbam capsules, is approved by the United States Food and Drug Administration as a treatment for children and adults with bile a... | Moderate | 1 | [
[
[
166,
24,
1108
]
],
[
[
166,
24,
1411
],
[
1411,
24,
857
],
[
857,
24,
1108
]
],
[
[
166,
24,
1411
],
[
1411,
63,
417
],
[
417,
24,
... | [
[
[
"Colesevelam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cholic Acid"
]
],
[
[
"Colesevelam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
... | Colesevelam may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Cholestyramine and Cholestyramine may cause a moderate interaction that could exacerbate diseases when taken with Cholic... |
DB00405 | DB01233 | 128 | 1,311 | [
"DDInter517",
"DDInter1197"
] | Dexbrompheniramine | Metoclopramide | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
128,
24,
1311
]
],
[
[
128,
24,
1020
],
[
1020,
24,
1311
]
],
[
[
128,
24,
643
],
[
643,
63,
1311
]
],
[
[
128,
63,
357
],
[
357,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidi... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Des... |
DB01224 | DB09104 | 623 | 286 | [
"DDInter1553",
"DDInter1118"
] | Quetiapine | Magnesium hydroxide | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
623,
24,
286
]
],
[
[
623,
24,
820
],
[
820,
23,
286
]
],
[
[
623,
63,
401
],
[
401,
23,
286
]
],
[
[
623,
74,
104
],
[
104,
23,... | [
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]... | Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine... |
DB00902 | DB01591 | 104 | 667 | [
"DDInter1168",
"DDInter1696"
] | Methdilazine | Solifenacin | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
104,
24,
667
]
],
[
[
104,
40,
11220
],
[
11220,
1,
667
]
],
[
[
104,
1,
830
],
[
830,
63,
667
]
],
[
[
104,
63,
1123
],
[
1123,
... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Methdilazine",
"{u} (Compound) resembles {v} (Compound)",
"Mequitazine"
],
[
"Mequitazine",
"{u} (Compound) r... | Methdilazine (Compound) resembles Mequitazine (Compound) and Mequitazine (Compound) resembles Solifenacin (Compound)
Methdilazine (Compound) resembles Phenindamine (Compound) and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin
Methdilazine may cause a moderate in... |
DB00518 | DB12130 | 510 | 1,017 | [
"DDInter35",
"DDInter1094"
] | Albendazole | Lorlatinib | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
510,
24,
1017
]
],
[
[
510,
62,
608
],
[
608,
23,
1017
]
],
[
[
510,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
510,
24,
629
],
[
629,
... | [
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Albendazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
... | Albendazole may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene... |
DB00738 | DB01142 | 485 | 1,264 | [
"DDInter1420",
"DDInter593"
] | Pentamidine | Doxepin | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
485,
24,
1264
]
],
[
[
485,
63,
508
],
[
508,
24,
1264
]
],
[
[
485,
24,
401
],
[
401,
24,
1264
]
],
[
[
485,
6,
8374
],
[
8374,
... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
... | Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Prometh... |
DB01191 | DB01276 | 1,039 | 123 | [
"DDInter518",
"DDInter706"
] | Dexfenfluramine | Exenatide | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
1039,
24,
123
]
],
[
[
1039,
63,
1338
],
[
1338,
24,
123
]
],
[
[
1039,
64,
939
],
[
939,
24,
123
]
],
[
[
1039,
24,
445
],
[
445,
... | [
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"... | Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Dexfenfluramine may lead to a major life threatening interaction when taken with Benzphetamine... |
DB00313 | DB06792 | 556 | 1,606 | [
"DDInter1913",
"DDInter1023"
] | Valproic acid | Lanthanum carbonate | Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investig... | Lanthanum carbonate is a phosphate binder commonly used in clinical practice. It is marketed under the trade name _Fosrenol_ by Shire Pharmaceuticals. It is the largest of all pills filled in community pharmacies. Sometimes patients forget that Fosrenol is not swallowed whole, but instead should be chewed. This has led... | Moderate | 1 | [
[
[
556,
24,
1606
]
],
[
[
556,
24,
1487
],
[
1487,
24,
1606
]
],
[
[
556,
24,
1487
],
[
1487,
62,
88
],
[
88,
24,
1606
]
],
[
[
556,
... | [
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychlor... | Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate
Valproic acid may cause a moderate interaction that could exacerbate diseases when t... |
DB01069 | DB09083 | 401 | 880 | [
"DDInter1533",
"DDInter996"
] | Promethazine | Ivabradine | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Major | 2 | [
[
[
401,
25,
880
]
],
[
[
401,
63,
480
],
[
480,
24,
880
]
],
[
[
401,
24,
659
],
[
659,
24,
880
]
],
[
[
401,
25,
1011
],
[
1011,
2... | [
[
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formot... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vi... |
DB01238 | DB09065 | 673 | 760 | [
"DDInter118",
"DDInter424"
] | Aripiprazole | Cobicistat | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
673,
24,
760
]
],
[
[
673,
63,
1101
],
[
1101,
23,
760
]
],
[
[
673,
24,
1374
],
[
1374,
23,
760
]
],
[
[
673,
63,
723
],
[
723,
... | [
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abi... |
DB00201 | DB01030 | 1,684 | 869 | [
"DDInter263",
"DDInter1835"
] | Caffeine | Topotecan | Caffeine is a drug of the methylxanthine class used for a variety of purposes, including certain respiratory conditions of the premature newborn, pain relief, and to combat drowsiness. Caffeine is similar in chemical structure to [Theophylline] and [Theobromine].[A187691,L9851] It can be sourced from coffee beans, but ... | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Minor | 0 | [
[
[
1684,
23,
869
]
],
[
[
1684,
6,
8374
],
[
8374,
45,
869
]
],
[
[
1684,
6,
2060
],
[
2060,
46,
869
]
],
[
[
1684,
21,
29276
],
[
29276,... | [
[
[
"Caffeine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Topotecan"
]
],
[
[
"Caffeine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Caffeine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Topotecan (Compound)
Caffeine (Compound) binds PIK3CA (Gene) and PIK3CA (Gene) is upregulated by Topotecan (Compound)
Caffeine (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Topotecan (Compound)
Caffeine may ca... |
DB04845 | DB09098 | 309 | 98 | [
"DDInter1001",
"DDInter1700"
] | Ixabepilone | Somatrem | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
309,
24,
98
]
],
[
[
309,
63,
168
],
[
168,
23,
98
]
],
[
[
309,
63,
671
],
[
671,
24,
98
]
],
[
[
309,
24,
159
],
[
159,
63,
... | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somatrem
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvast... |
DB00620 | DB11988 | 175 | 270 | [
"DDInter1855",
"DDInter1321"
] | Triamcinolone | Ocrelizumab | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
175,
24,
270
]
],
[
[
175,
23,
1193
],
[
1193,
23,
270
]
],
[
[
175,
62,
1461
],
[
1461,
23,
270
]
],
[
[
175,
24,
713
],
[
713,
... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Triamcinolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],... | Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Vitamin E an... |
DB00563 | DB12332 | 663 | 1,619 | [
"DDInter1174",
"DDInter1626"
] | Methotrexate | Rucaparib | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
663,
24,
1619
]
],
[
[
663,
24,
259
],
[
259,
24,
1619
]
],
[
[
663,
24,
151
],
[
151,
63,
1619
]
],
[
[
663,
63,
556
],
[
556,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus ... |
DB00063 | DB00476 | 366 | 109 | [
"DDInter659",
"DDInter608"
] | Eptifibatide | Duloxetine | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Moderate | 1 | [
[
[
366,
24,
109
]
],
[
[
366,
24,
758
],
[
758,
1,
109
]
],
[
[
366,
25,
1409
],
[
1409,
63,
109
]
],
[
[
366,
25,
273
],
[
273,
24... | [
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
]
],
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxetine"
],
... | Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine (Compound) resembles Duloxetine (Compound)
Eptifibatide may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate dis... |
DB00069 | DB01097 | 367 | 1,377 | [
"DDInter946",
"DDInter1033"
] | Interferon alfacon-1 | Leflunomide | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
367,
25,
1377
]
],
[
[
367,
24,
242
],
[
242,
63,
1377
]
],
[
[
367,
25,
1477
],
[
1477,
63,
1377
]
],
[
[
367,
24,
126
],
[
126,
... | [
[
[
"Interferon alfacon-1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
... | Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Interferon alfacon-1 may lead to a major life threatening interaction when taken with Telbivudine and... |
DB00254 | DB08938 | 964 | 1,384 | [
"DDInter598",
"DDInter1112"
] | Doxycycline | Magaldrate | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and... | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Moderate | 1 | [
[
[
964,
24,
1384
]
],
[
[
964,
24,
1252
],
[
1252,
23,
1384
]
],
[
[
964,
63,
362
],
[
362,
24,
1384
]
],
[
[
964,
1,
1669
],
[
1669,
... | [
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
... | Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may... |
DB01009 | DB06209 | 935 | 256 | [
"DDInter1009",
"DDInter1508"
] | Ketoprofen | Prasugrel | Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Major | 2 | [
[
[
935,
25,
256
]
],
[
[
935,
6,
1829
],
[
1829,
45,
256
]
],
[
[
935,
21,
28681
],
[
28681,
60,
256
]
],
[
[
935,
62,
752
],
[
752,
... | [
[
[
"Ketoprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
]
],
[
[
"Ketoprofen",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",
"Prasugrel"
... | Ketoprofen (Compound) binds ALB (Gene) and ALB (Gene) is bound by Prasugrel (Compound)
Ketoprofen (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound)
Ketoprofen may cause a minor interaction that can limit clinical effects when taken with Cimetidine and ... |
DB00515 | DB00743 | 589 | 808 | [
"DDInter387",
"DDInter792"
] | Cisplatin | Gadobenic acid | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Gadobenic acid, usually available in the salt form gadobenate dimeglumine, is a linear MRI gadolinium-based contrast agent (GBCA) used primarily for MR imaging of the liver. It differs from other GBCAs due to the benzene ring that confers weak protein binding, thus leading to an increased R1 and R2 relaxivity. As gadob... | Moderate | 1 | [
[
[
589,
24,
808
]
],
[
[
589,
21,
28769
],
[
28769,
60,
808
]
],
[
[
589,
63,
322
],
[
322,
24,
808
]
],
[
[
589,
24,
663
],
[
663,
... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadobenic acid"
]
],
[
[
"Cisplatin",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"{u} (Side... | Cisplatin (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Gadobenic acid (Compound)
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when ta... |
DB09082 | DB12825 | 659 | 1,375 | [
"DDInter1934",
"DDInter1032"
] | Vilanterol | Lefamulin | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Moderate | 1 | [
[
[
659,
24,
1375
]
],
[
[
659,
24,
159
],
[
159,
63,
1375
]
],
[
[
659,
62,
870
],
[
870,
24,
1375
]
],
[
[
659,
63,
455
],
[
455,
... | [
[
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Vilanterol may cause a minor interaction that can limit clinical effects when taken with Fludrocortisone an... |
DB00692 | DB14509 | 274 | 1,399 | [
"DDInter1448",
"DDInter1081"
] | Phentolamine | Lithium carbonate | Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
274,
24,
1399
]
],
[
[
274,
24,
820
],
[
820,
24,
1399
]
],
[
[
274,
63,
475
],
[
475,
24,
1399
]
],
[
[
274,
23,
1254
],
[
1254,
... | [
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
... | Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Morphine... |
DB00188 | DB09074 | 168 | 1,362 | [
"DDInter222",
"DDInter1327"
] | Bortezomib | Olaparib | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
168,
24,
1362
]
],
[
[
168,
24,
896
],
[
896,
24,
1362
]
],
[
[
168,
23,
353
],
[
353,
24,
1362
]
],
[
[
168,
63,
491
],
[
491,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Griseofulvin and Griseofulv... |
DB01156 | DB04896 | 593 | 901 | [
"DDInter252",
"DDInter1220"
] | Bupropion | Milnacipran | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the a... | Major | 2 | [
[
[
593,
25,
901
]
],
[
[
593,
25,
41
],
[
41,
1,
901
]
],
[
[
593,
64,
1349
],
[
1349,
40,
901
]
],
[
[
593,
6,
7390
],
[
7390,
45,... | [
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Milnacipran"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
... | Bupropion may lead to a major life threatening interaction when taken with Levomilnacipran and Levomilnacipran (Compound) resembles Milnacipran (Compound)
Bupropion may lead to a major life threatening interaction when taken with Meperidine and Meperidine (Compound) resembles Milnacipran (Compound)
Bupropion (Compound)... |
DB00631 | DB04835 | 372 | 1,655 | [
"DDInter405",
"DDInter1125"
] | Clofarabine | Maraviroc | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Mara... | Moderate | 1 | [
[
[
372,
24,
1655
]
],
[
[
372,
21,
28792
],
[
28792,
60,
1655
]
],
[
[
372,
63,
1419
],
[
1419,
24,
1655
]
],
[
[
372,
24,
888
],
[
888,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maraviroc"
]
],
[
[
"Clofarabine",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal disorder"
],
[
"Gastrointestinal disorder",... | Clofarabine (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Maraviroc (Compound)
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate dis... |
DB00688 | DB01017 | 955 | 1,669 | [
"DDInter1251",
"DDInter1224"
] | Mycophenolate mofetil | Minocycline | Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as [Cyclosporine] and corticosteroids to prevent organ rejection after hepatic, ren... | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | Moderate | 1 | [
[
[
955,
24,
1669
]
],
[
[
955,
63,
1572
],
[
1572,
1,
1669
]
],
[
[
955,
63,
1545
],
[
1545,
40,
1669
]
],
[
[
955,
24,
1620
],
[
1620,
... | [
[
[
"Mycophenolate mofetil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
]
],
[
[
"Mycophenolate mofetil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deme... | Mycophenolate mofetil may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline (Compound) resembles Minocycline (Compound)
Mycophenolate mofetil may cause a moderate interaction that could exacerbate diseases when taken with Oxytetracycline and Oxytetracycline (C... |
DB00559 | DB12130 | 152 | 1,017 | [
"DDInter223",
"DDInter1094"
] | Bosentan | Lorlatinib | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Major | 2 | [
[
[
152,
25,
1017
]
],
[
[
152,
62,
608
],
[
608,
23,
1017
]
],
[
[
152,
63,
590
],
[
590,
24,
1017
]
],
[
[
152,
24,
175
],
[
175,
... | [
[
[
"Bosentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Bosentan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
... | Bosentan may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide... |
DB00705 | DB14723 | 441 | 159 | [
"DDInter496",
"DDInter1026"
] | Delavirdine | Larotrectinib | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Major | 2 | [
[
[
441,
25,
159
]
],
[
[
441,
23,
222
],
[
222,
23,
159
]
],
[
[
441,
25,
1135
],
[
1135,
23,
159
]
],
[
[
441,
62,
63
],
[
63,
24,... | [
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
]
],
[
[
"Delavirdine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutr... | Delavirdine may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Delavirdine may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.